

## Bundled Payments for Care Improvement (BPCI) Advanced Annual Check-in Questionnaire

[illegible]

1

1

### Purpose:

Participants' activities and barriers related to designing and implementing the BPCI Advanced Model

1

**Instructions:**

The first part of the study was a pilot study. The purpose of the pilot study was to determine the feasibility of the study and to estimate the sample size required for the main study. The pilot study was conducted with 10 participants. The results of the pilot study showed that the study was feasible and that the sample size required for the main study was 100 participants.

The main study was conducted with 100 participants. The participants were recruited from a local community center. The participants were randomly assigned to two groups: the experimental group and the control group. The experimental group received the intervention, and the control group did not receive the intervention. The intervention was a 12-week program of physical activity and education. The physical activity component of the intervention consisted of three sessions per week, each lasting 30 minutes. The education component of the intervention consisted of two sessions per week, each lasting 30 minutes. The control group received no intervention.

The primary outcome of the study was the change in blood pressure (BP) from baseline to 12 weeks. The secondary outcomes of the study were the change in body mass index (BMI), the change in waist circumference (WC), and the change in heart rate (HR). The results of the study showed that the experimental group had a significantly greater reduction in BP, BMI, WC, and HR compared to the control group.


The results of the study suggest that the intervention is effective in reducing BP, BMI, WC, and HR. The intervention may be a useful tool for the prevention and management of hypertension and related conditions. Further research is needed to confirm these findings and to determine the long-term effects of the intervention.

-

- 
- 

“Open with”

- 



no later than **September 23, 2019 at 11:59PM ET** [or](#) [or](#)

M r d M r r d d d r  
r rd r M     
d d M

101

☐  
☐  
☐  
☐  
☐

☐

☐

☐

☐

1

□ □ □ □

□ □ □ □ □

□ □ □ □ □

1001

## Participant Profile

☐

☐

☐

9

111

## Care Redesign Plan

1001

□ r □ □ □ □ □ D □ □ □ □ r □ □ □

[illegible]

**D** **r** **d** **d** **R**

☐  
☐  
☐  
☐  
☐

[illegible][illegible]

## CEHRT Use

1. *To meet this criterion, at least 75 percent of eligible clinicians in each participating APM Entity group, or each hospital if hospitals are the APM Entities, to use CEHRT to document and communicate clinical care.*



☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ r ☐ ☐ ☐ ☐ ☐ ☐ d ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ E R ☐ ☐ ☐ ☐ r ☐ ☐ ☐ ☐ ☐

☐

☐  
☐  
☐

$\frac{d}{dt} \left( \frac{1}{2} m v^2 + U(r) \right) = 0$

□ □ □ □ □ □ □ □ □ □ □ □ □

## Partner Agreements

1. **Definition:** A **Discrete-Time Signal** is a signal that is defined only at discrete intervals of time. It is represented by a sequence of values, often denoted as  $x[n]$ , where  $n$  is the discrete time index.

□ □ □ □ □

□□□ □□□□□□□□ r□□□□□□□□□□□□□□□□□□□ d□□□ r□□□ □□□□□□ □□□□□□□□□□ r□□□□□□□□□□ r□□□□□□□□□□ r□□□

☐

☐

☐

☐

☐

[illegible]

☐☐☐☐☐

[illegible]

- |  |                          |                          |                          |                          |
|--|--------------------------|--------------------------|--------------------------|--------------------------|
|  | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
|  | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |

4.

$\frac{1}{n} \sum_{i=1}^n x_i = \bar{x}$

Diagram illustrating the structure of a DNA sequence. The sequence is represented by a horizontal bar divided into segments. The segments are labeled with letters: D, r, d, r. The segments are color-coded: D is blue, r is green, d is red, and r is green. The segments are arranged in a sequence: D, r, d, r. The segments are connected by lines, indicating a continuous sequence.

- 1111

□ □ □ □ □ □ □ □ □ □ □ □ □

115

□ □ □ □ □ □ □ □ □ □ □ □ □

☐  
☐  
☐  
☐  
☐



□□□□ □□□□ d □□ r □□□□□□□□ d r □□□□□□□□□□ r □ d the Participant's d □□□□□□□□□□  
□ □□□□□□□□□□□□□□□ r □□ r □□ rd □□□□□□□□□□□□□□□□ rr □□□□ □□□□□□

- [illegible]

### Internal Cost Savings (ICS)

[illegible]

- ☐

☐

☐

☐ If selected ‘Yes’ to question 1, has the Participant \_\_\_\_\_d \_\_\_\_\_r \_\_\_\_\_d  
\_\_\_\_\_  
\_\_\_\_\_r \_\_\_\_\_  
☐

- 

### Net Payment Reconciliation Amount (NPRA)

**D** **r** **R** **d** **d** **r**

**r** **r** **d** **d** **[Performance Period 1: October 1, 2018 through June 30, 2019]**

- □ □ □ □ □

- 

## Compliance Plan

- ## Waivers (Fraud & Abuse Waivers and Medicare Payment Policy Waivers)

Participant Profile Selection Does Not Limit Use of Waivers”

[illegible]

□ □ □

[illegible]

□ □ □

If selected ‘Yes’ to question “Do you have any other information or documents?”

Researcher’s name:

E-mail address:

Phone number:

-  

[illegible]

111

[illegible]

333

[illegible]

□ □ □ □ □

[illegible]

□ □ □ □ □ □

[illegible]

-   
  


1111

[illegible]

□ □ □

[illegible]

word

[illegible]

□r□□□□□□r□□ □□□□r□□□□□□ □□□□□□□□ □□□□ □□□r□□□□d□□□□□

11 of 11

□ □ □

☐ If selected 'Other' to question

□ □ □ □ □ □ □ □ □ □ □ □ □ □ □

□ □ □ □ □

1

1000000

[illegible]



[illegible][illegible]

1



1

5



## BPCI Advanced Impact







☐ If selected 'Yes' to either question 1 or 2, ☐ **d** ☐ **r** ☐

☐

□

□

1

3

1

☐☐☐ ☐

10



[illegible]

## Beneficiary Impact

The complaint process in place does not have to be solely for Beneficiaries in the BPCI Advanced Model. However the current complaint system in place must track complaints made by Beneficiaries in the BPCI Advanced Model.

☐ If selected 'Yes' to question ☐ d ☐ r ☐ r

☐ r ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ r ☐ ☐ ☐

ur

			r			
--	--	--	---	--	--	--

D r

r r d r

1

□ □ □ r □ □





5

[illegible]

d

☐ ☐☐ ☐☐☐☐☐☐☐☐ r ☐☐☐☐

□ □ □ □ □ R □ □ □ □ □

11/11/2019



5

5

## Document Submission

d               M   

5

[illegible]

□

☐

9

☐

111

☐

[illegible]

- ☐

☐

☐

☐

☐

## Self-disclosed Investigations or Sanctions

[illegible]

- □ □

2. I selected 'Yes' to the question: "Do you have any information about the [redacted]?"  
[redacted]  
[redacted] M [redacted] [redacted]  
*Additional information is located under Article 13 of the Participation Agreement.*

- □ □ □ □ □ □

### Other Issues Not Previously Listed

- 9